Most importantly, increasing studies pointed out that the inhibition of amyloid aggregation and LLPS has shown initial promise for the therapeutic treatment of T2DM and clinical applications, suggesting IAPP as a potential therapeutic target of T2DM [81]. The gene discussed is IAPP; the disease is type 2 diabetes mellitus.